

25<sup>th</sup> March 2025

Dear Valued Customer,

**Re: Update on New Zealand supply of Pegasys® (peginterferon alfa-2a)**

Echo Therapeutics Pty Ltd is the registered sponsor of Pegasys® (peginterferon alfa-2a) Medsafe Ref: TT50-6071/1c. We would like to provide an update on the current supply status of Pegasys® for your patients.

Presently, we are down to just under three months supply, with no definitive timeline of when replenishment stock of ANZ labelled Pegasys® will become available. Both Medsafe and PHARMAC have been notified of this anticipated shortage. While we are hopeful that there will be no significant supply interruption, we are mitigating with options such as supplying foreign-labelled stock under Section 29 to ensure patients can continue to access treatment.

In the unlikely event of a protracted shortage, in addition to the controlled release strategies already in place, we seek your assistance with treatment management strategies for newly initiated and existing patients. Overseas, there have been examples of alternative dosing being considered, or even delaying starting new patients on Pegasys®. Whilst Echo Therapeutics is exploring all supply options, we request your support to help manage patients' disease and expectations during this time. Additional information and guidance is available at the [HSANZ website](#) including a [video link](#) where Dr Cecily Forsyth discusses possible strategies to consider in your practice.

We believe that with urgent support from yourself and/or via a consultative group of physicians of the HSANZ, these treatment management strategies will help ensure any disruption to patient care (whether new or existing patients) can be mitigated as soon as possible, i.e. well ahead of any potential disruption to supply. Thank you in advance for considering this request.

Please forward this notification to any colleagues to whom it would be of interest.

Should you wish to discuss further or require additional information, please don't hesitate to contact Echo Therapeutics on +64 9 8862449 or [connect@echotherapeutics.net](mailto:connect@echotherapeutics.net).

Kind Regards,



Jude D'Silva

Managing Director  
Echo Therapeutics